Is STRM undervalued? Intrinsic value estimate stands at $-2.1.
Get informed when a big investor buys or sells
+ Follow$-2.07
Overvalued by 138.7% based on the discounted cash flow analysis.
Streamline Health Solutions (STRM) currently reports a DCF fair value of $-2.1. Use the charts on this page to explore Streamline Health Solutions's DCF fair value history and peer comparisons.
Streamline Health Solutions's discounted cash flow (DCF) fair value estimate is $-2.1, about 138.7% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.
Start with the current DCF fair value of $-2.1, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Streamline Health Solutions, and consider following STRM for alerts when major investors trade the stock.
Streamline Health Solutions is classified in the Technology sector. On DCF fair value, it currently shows $-2.1. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Technology are usually more informative than comparing STRM with unrelated industries.